FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to molecular biology, biotechnology, genetic engineering and medicine, and can be used for relief of manifestations of human body conditions associated with reduced expression of P4NA2 gene and/or reduced amount of protein prolyl 4-hydroxy acid alpha 2. Disclosed is a genetic construct based on a non-viral DNA vector comprising a P4NA2 gene cDNA selected from genetic constructs, each of which represents a genetic construct based on a DNA vector comprising a cDNA of the P4NA2 gene, with a coding protein sequence of prolyl 4-hydroxy-oxidase alpha 2, with 5' deletions and 3'-non-translated regions, specifically obtained based on the native non-modified cDNA region of the P4NA2 gene SEQ ID No: 1 or modified cDNA of the P4NA2 gene, wherein the modified P4NA2 gene cDNA used is SEQ ID No: 2, or SEQ ID No: 3, or SEQ ID No: 4, or SEQ ID No: 5, or SEQ ID No: 6, or SEQ ID No: 7, or a combination of these genetic constructs, each of which also contains regulatory elements providing a high level of expression of the P4NA2 gene in eukaryotic cells. Method of producing a genetic construct and use thereof are also provided.
EFFECT: invention allows increasing the amount of prolyl 4-hydroxylase alpha 2 protein in eukaryotic cells.
6 cl, 28 dwg, 20 ex
